...
首页> 外文期刊>Familial cancer >The association between prognosis of breast cancer and first-degree family history of breast or ovarian cancer: a systematic review and meta-analysis
【24h】

The association between prognosis of breast cancer and first-degree family history of breast or ovarian cancer: a systematic review and meta-analysis

机译:乳腺癌乳腺癌和一级家族史的预后与乳腺癌的关联:系统审查和荟萃分析

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Whether a positive family history of breast cancer or ovarian cancer (FHBOC) would affect the prognosis of breast cancer is still up for debate and further study. This meta-analysis was performed to clarify this issue. We reviewed two databases (PubMed and CNKI) for research articles published at any time from the inception of these databases to April 1, 2016 for articles detecting the impact of FHBOC on the prognosis of breast cancer. A meta-analysis was conducted to generated combined hazard ratios (HR) with 95% confidence intervals (CI) for overall survival (OS) and breast cancer-specific survival (BCSS). Eighteen studies were included in our qualitative analysis, with 15 studies ultimately part of the quantitative analysis. The pooled results demonstrated that a positive FHBOC was associated with better OS (0.89, 95% CI 0.83-0.95) and BCSS (0.90, 95% CI 0.82-0.99). In subgroup analyses, several subgroups (maximally adjusted studies, population based studies, high quality studies, family history of breast cancer, studies from Europe, studies from Asia, 1 affected relative, or tumor size > 2 cm), a positive first-degree FHBOC was associated with better prognosis of breast cancer. Notably, for those patients who underwent breast-conserving surgery, first-degree FHBOC was not a risk factor for OS (HR 1.08, 95% CI 0.53-2.21). Our meta-analysis demonstrated that a first-degree FHBOC was associated with better OS and BCSS in patients with breast cancer. These findings support that clinical management should not differ between women with and without FHBOC.
机译:乳腺癌或卵巢癌(FHBOC)的阳性家庭史是否会影响乳腺癌的预后仍然用于辩论和进一步研究。此元分析进行了澄清此问题。我们审查了两种数据库(PubMed和CNKI),用于在从这些数据库开始到2016年4月1日出版的研究文章,以便检测FHBOC对乳腺癌预后的影响。进行META分析以产生95%置信区间(CI)的组合危险比(HR),用于整体存活(OS)和乳腺癌特异性存活(BCSS)。在我们的定性分析中包含十八研究,最终有15项研究的定量分析。汇总结果表明,阳性FHBOC与更好的OS(0.89,95%CI 0.83-0.95)和BCSS(0.90,95%CI 0.82-0.99)相关。在亚组分析中,几个亚组(最大调整的研究,基于人口的研究,高质量的研究,乳腺癌的家族史,欧洲的研究,亚洲的研究,1种受影响的亲属或肿瘤大小> 2厘米),是一定的一定程度FHBOC与更好的乳腺癌预后有关。值得注意的是,对于那些接受哺乳手术的患者,一级FHBOC不是OS的危险因素(HR 1.08,95%CI 0.53-21.21)。我们的META分析表明,乳腺癌患者中的一级FHBOC与更好的OS和BCS相关。这些调查结果支持临床管理不应与没有FHBOC的妇女之间的妇女不同。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号